Experiences with
Imbruvica843 public posts
Want to take advantage of all our features? Just log in!
or
Factors Identified for Risk of Second Cancer in CLL Following BTK Inhibition
The study analyzed 691 patients with CLL who were treated with either acalabrutinib (Calquence) or ibrutinib (Imbruvica) and developed a second primary malignancy. The rate of developing a second primary neoplasia in patients with CLL treated with this class of agents was 7.6% at 3 years.
EU Panel Backs Expanded Indication of Ibrutinib Combos in CLL
Friday, Jun 28, 2019
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the indications of ibrutinib (Imbruvica) to include use in combination with obinutuzumab (Gazyva) for adult patients with previously untreated chronic lymphocytic leukemia